$ 48.59
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Strong growth
About
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body....
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of AKRO is 72 and suggests 49% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
